Liver Cancer

Introduction

A liver cancer diagnosis raises many questions at once — what kind of cancer it is, how far it has spread, what the rest of the liver looks like, and which treatment makes sense. Liver cancer is not a single disease. It includes several different tumours that behave differently and are treated differently. Some are confined to one part of the liver and can be removed with surgery. Others are more advanced and are managed with treatments that target the tumour through the bloodstream or directly within the liver.

This guide is written for patients and families who already have a diagnosis and are now working through the next steps with their medical team. It explains what liver cancer is, how doctors classify and stage it, the main treatment options — from surgery and transplantation to locoregional therapies, chemotherapy, targeted therapy, and immunotherapy — and what life with and after treatment can look like. It is meant to give you the broad map so that conversations with your team make more sense.

What Is Liver Cancer?

Liver cancer is the general name for cancers that begin in the liver (primary liver cancer) or that spread to the liver from another organ (secondary or metastatic liver cancer). The liver sits in the upper right side of the abdomen, under the ribs. It performs many essential tasks — processing nutrients, making proteins, clearing toxins from the blood, producing bile to help digest fats, and storing energy.

The liver is also unusual among organs in its ability to regenerate. A healthy liver can regrow after part of it is removed, which is one reason surgery to take out a tumour is possible for some patients.

Liver cancer is managed by a team of specialists. This usually includes a hepatologist (a doctor who specialises in liver disease), a surgical oncologist or hepatobiliary surgeon (often called an HPB surgeon, for hepatopancreatobiliary), a medical oncologist, an interventional radiologist, a diagnostic radiologist, and a pathologist. Major decisions are usually made in a multidisciplinary tumour board, where these specialists review imaging, pathology, and liver function together.

Types of Liver Cancer

Knowing which type of liver cancer is involved shapes everything that follows — the staging, the treatment options, and the outlook.

Hepatocellular carcinoma (HCC)

Hepatocellular carcinoma is the most common primary liver cancer. It begins in the main liver cells (hepatocytes). HCC often develops in a liver that is already affected by long-standing damage — most commonly cirrhosis from chronic hepatitis B infection, chronic hepatitis C infection, long-term alcohol use, or non-alcoholic fatty liver disease (now often called metabolic dysfunction-associated steatotic liver disease, or MASLD). Because HCC usually arises in a background of liver disease, treatment depends not only on the tumour but also on how well the rest of the liver is working.

Intrahepatic cholangiocarcinoma

Cholangiocarcinoma is a cancer of the bile ducts. When it begins in the small bile ducts inside the liver, it is called intrahepatic cholangiocarcinoma. It is less common than HCC but is rising in many countries. Treatment principles differ from HCC, and chemotherapy plays a larger role.

Secondary (metastatic) liver tumours

The liver is a common site for cancer to spread from elsewhere in the body. Cancers of the colon and rectum are the most frequent source, but breast, lung, pancreas, stomach, neuroendocrine, and other cancers can also spread to the liver. These are not called liver cancer in the strict sense — they are the original cancer that has travelled to the liver. Treatment is guided by the original cancer type. For colorectal liver metastases, surgery to remove the deposits is sometimes possible and can offer long-term control.

Hepatoblastoma

Hepatoblastoma is a rare liver cancer that almost always occurs in young children. It is discussed in the children’s section later in this article.

Other rare liver cancers

Less common types include fibrolamellar carcinoma (a variant of HCC seen in younger patients without underlying liver disease), angiosarcoma of the liver, and hepatic lymphoma. These are uncommon and are managed at specialised centres.

Causes and Risk Factors

Liver cancer rarely appears in a healthy liver. Most cases of HCC develop against a background of chronic liver injury that, over years, causes scarring (fibrosis), then cirrhosis, then in some people, cancer. Understanding the cause matters because controlling it can reduce the risk of further tumours and improve overall liver function.

Common risk factors include:

• Chronic hepatitis B infection — a leading cause of HCC worldwide, including in India and across Asia.
• Chronic hepatitis C infection — another major cause, now much more treatable with modern antiviral medicines.
• Cirrhosis from any cause — including alcohol-related liver disease, non-alcoholic fatty liver disease, autoimmune hepatitis, haemochromatosis (iron overload), and Wilson’s disease.
• Heavy long-term alcohol use.
• Type 2 diabetes and obesity — through their link with fatty liver disease.
• Aflatoxin exposure — a toxin produced by moulds that can contaminate stored grains and nuts in some regions.
• Smoking.
• Family history of liver cancer or certain inherited liver conditions.

For cholangiocarcinoma, additional risk factors include primary sclerosing cholangitis, certain bile duct cysts, and chronic infection with liver flukes in some regions.

Many people with liver cancer have more than one risk factor. Some have none that can be clearly identified.

Signs and Symptoms

Most readers of this article already have a diagnosis. This section is included to help you recognise changes that should be reported to your team during treatment and follow-up, and to understand what may have prompted the original investigation.

Liver cancer often causes no symptoms in its early stages, particularly when it develops in someone who is already being monitored for chronic liver disease. When symptoms occur, they may include:

• Persistent discomfort or a dull ache in the upper right abdomen
• A feeling of fullness or a lump in the upper abdomen
• Unintended weight loss
• Loss of appetite
• Nausea and vomiting
• Tiredness and weakness
• Yellowing of the skin and eyes (jaundice)
• Pale stools and dark urine
• Swelling of the abdomen from fluid build-up (ascites)
• Easy bruising or bleeding
• Itching

During follow-up, new or worsening symptoms of this kind should be reported promptly. They do not always mean the cancer has come back — many can be caused by underlying liver disease — but they are worth investigating.

Diagnosis and Staging

Diagnosis of liver cancer combines imaging, blood tests, and sometimes a biopsy. Once cancer is confirmed, staging tests describe how far it has spread and how well the liver is working.

Imaging

• Ultrasound — often the first test, particularly in surveillance of people with cirrhosis or chronic hepatitis B.
• Triple-phase or four-phase contrast-enhanced CT of the abdomen — shows the liver during different phases of blood flow and can identify tumours with characteristic patterns.
• MRI of the liver, often with a liver-specific contrast agent — gives detailed images of the tumour and the rest of the liver, and is particularly useful for small lesions.
• Chest CT to check for spread to the lungs.
• PET-CT in selected cases, particularly for cholangiocarcinoma or when there is concern about distant spread.
• Bone scan if there is concern about bone involvement.

For HCC, the diagnosis can sometimes be made from imaging alone when the tumour shows a characteristic pattern of contrast uptake in a patient with cirrhosis. In other cases, and for most cholangiocarcinomas, a biopsy is needed.

Blood tests

• Liver function tests (bilirubin, albumin, INR, transaminases) to assess how well the liver is working.
• Tumour markers — alpha-fetoprotein (AFP) for HCC, CA 19-9 for cholangiocarcinoma, and CEA for colorectal liver metastases. These are not diagnostic on their own but help in the overall picture.
• Tests for hepatitis B and C infection.
• Kidney function, full blood count, and clotting tests.

Biopsy

A biopsy, in which a thin needle is used to take a small sample of the tumour, may be done when imaging is not conclusive or when the cancer type needs to be confirmed before systemic treatment. It is not always required for HCC. Your team will explain whether a biopsy is needed in your case.

Assessing the rest of the liver

Because treatment depends heavily on liver function, doctors use specific tools to grade how well the liver is working:

• Child–Pugh score — combines bilirubin, albumin, clotting, ascites, and brain effects (encephalopathy) into grades A, B, or C.
• MELD score — a number that estimates how well the liver is working and is used in transplant decisions.
• CT volumetry — measures the volume of liver that would remain after a planned resection (the future liver remnant).
• Indocyanine green (ICG) clearance test — a dye test that measures how efficiently the liver processes substances.

Staging systems

Several staging systems are used in liver cancer. For HCC, the Barcelona Clinic Liver Cancer (BCLC) system is widely used internationally and combines tumour stage, liver function, and the patient’s general condition to suggest a treatment pathway. The traditional TNM system (tumour, nodes, metastasis) is used for cholangiocarcinoma and other liver cancers. Your team will explain which staging applies in your case and what it means.

Treatment and Management

Treatment of liver cancer depends on the type of cancer, its stage, the condition of the rest of the liver, your overall health, and your preferences. Major societies including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), the European Society for Medical Oncology (ESMO), and the National Comprehensive Cancer Network (NCCN) describe a tiered approach in which several modalities can be used alone or in combination.

The most common modalities are surgery (resection or transplantation), locoregional therapies that target the tumour within the liver, and systemic therapy that travels through the bloodstream. Many treatment plans use more than one of these.

Surgery: liver resection (hepatectomy)

Liver resection is the removal of the part of the liver containing the tumour, leaving enough healthy liver behind to keep the body functioning. The remaining liver regenerates over weeks to months. Resection is considered for patients whose tumour can be completely removed and whose remaining liver is healthy enough to support life.

The amount removed depends on the tumour’s size and position:

• Wedge resection — removes a small piece containing the tumour, used for small superficial tumours.
• Segmentectomy — removes one of the liver’s eight anatomical segments.
• Sectionectomy or bisegmentectomy — removes two adjacent segments.
• Hemihepatectomy — removes the right or left half of the liver.
• Extended hepatectomy — removes more than half of the liver, possible only when the remaining liver is healthy and large enough.

If the planned remnant would be too small, a procedure called portal vein embolisation can be done several weeks before surgery to make the remaining side grow. A more recent technique called ALPPS (Associating Liver Partition and Portal vein ligation for Staged hepatectomy) is used in selected cases at experienced centres.

Resection can be performed open (through one larger incision) or minimally invasively (laparoscopic or robotic). For carefully selected tumours, minimally invasive surgery is associated with less blood loss, less pain, and shorter hospital stay. For very large, centrally located, or anatomically complex tumours, open surgery often remains the safer choice. The right approach depends on the tumour, the liver, and the surgical team’s experience.

The goal of surgery is what oncologists call an R0 resection — removing all visible cancer with a clear margin of healthy tissue around it.

Surgery: liver transplantation

In liver transplantation, the diseased liver is removed entirely and replaced with a healthy donor liver. Transplant treats both the cancer and any underlying liver disease at the same time. It is most often considered for patients with HCC who have significant cirrhosis — where removing part of the liver would leave too little to function.

The Milan criteria are the most widely used standard for HCC transplant eligibility: a single tumour up to 5 cm, or up to three tumours each up to 3 cm, with no major blood vessel involvement and no spread outside the liver. Some centres use extended criteria, such as the UCSF criteria, for selected patients with slightly larger tumours.

Two donor pathways exist:

• Deceased donor liver transplantation — the donor liver comes from someone who has died and consented to organ donation. Wait times depend on local organ availability and allocation systems.
• Living donor liver transplantation (LDLT) — a portion of the liver, usually the right lobe, is donated by a healthy living person, often a relative. Both the donor’s remaining liver and the transplanted portion regenerate to near-normal size within weeks. Living donor transplantation is the dominant form in many parts of South Asia, including India, where deceased donor availability is more limited.

While waiting for transplant, a tumour may be controlled with locoregional therapy. This is called bridging therapy. When tumours are slightly outside the criteria, locoregional treatment is sometimes used to shrink them back into eligibility — called downstaging.

Locoregional therapies

Locoregional therapies treat the tumour directly within the liver without removing it. They are used when surgery is not possible, as a bridge to transplant, in combination with systemic therapy, or for selected small tumours where ablation can give results comparable to resection.

• Radiofrequency ablation (RFA) and microwave ablation (MWA) — a needle is guided into the tumour and used to heat and destroy the cancer cells. Often used for small tumours, particularly those under 3 cm.
• Transarterial chemoembolisation (TACE) — chemotherapy is delivered directly into the artery feeding the tumour, combined with material that blocks the blood supply. Commonly used for intermediate-stage HCC and as a bridge to transplant.
• Transarterial radioembolisation (TARE / Y-90) — tiny radioactive beads are delivered into the artery feeding the tumour, giving radiation from inside.
• Stereotactic body radiation therapy (SBRT) — precisely focused external-beam radiation, used in selected cases.

Systemic therapy

Systemic therapy uses medicines that travel through the bloodstream to reach cancer cells throughout the body.

• Immunotherapy — combinations such as atezolizumab with bevacizumab, and other immune checkpoint inhibitor regimens, are now widely used as first-line treatment for advanced HCC in major international guidelines.
• Targeted therapy — medicines such as sorafenib, lenvatinib, regorafenib, and cabozantinib are used in HCC, depending on the line of treatment and prior therapies.
• Chemotherapy — plays a larger role for intrahepatic cholangiocarcinoma and for liver metastases from cancers such as colorectal cancer. Gemcitabine-based combinations are commonly used in cholangiocarcinoma.
• Targeted treatment based on molecular testing — certain biliary tract cancers have genetic changes (such as FGFR2 fusions or IDH1 mutations) that can be targeted with specific medicines. Molecular testing is increasingly part of standard work-up for cholangiocarcinoma.

Supportive and palliative care

Supportive care helps with symptoms, nutrition, and quality of life at every stage of treatment. When cure-directed treatment is no longer possible, palliative care takes the lead, focusing on relieving symptoms such as pain, jaundice, itching, ascites, and fatigue. Palliative care can be combined with active cancer treatment at any stage — it is not only for the end of life.

Recovery After Treatment

Recovery looks different depending on which treatments you have had.

After liver resection

Most patients stay in hospital for about 5 to 10 days after a resection, with one to three days in an intensive care unit for major operations. Pain is controlled with epidural or intravenous medication initially, then oral painkillers. Early walking is encouraged within a day or two to reduce the risk of blood clots and chest infections. Diet is reintroduced gradually.

At home, fatigue is common for several weeks. Light walking is encouraged daily, while heavy lifting and strenuous activity are usually avoided for around six weeks after open surgery, often less after laparoscopic surgery. Most people who have a resection feel substantially better by 6 to 12 weeks. The remaining liver regenerates over several months.

After liver transplantation

Transplant recovery is longer. Hospital stay is typically 2 to 4 weeks. Immunosuppressive medicines are started immediately and adjusted carefully over the first weeks. Many recipients describe returning to a stable new normal at around six months to a year, although everyday activities resume much earlier.

After locoregional therapy

Ablation, TACE, and TARE are usually done with shorter hospital stays — sometimes overnight or a few days. Some patients experience a post-embolisation syndrome of fever, nausea, and pain for a few days after TACE, which usually settles with supportive treatment.

During systemic therapy

Recovery is ongoing rather than a single event. Energy levels and side effects vary by medicine. Most regimens are given in cycles, with rest days in between. Your team will explain what to expect and how to manage side effects such as fatigue, skin changes, blood pressure changes, diarrhoea, or immune-related effects with immunotherapy.

Monitoring and Follow-up

Follow-up after liver cancer treatment is important for catching recurrence early, monitoring liver function, and managing underlying liver disease. The exact schedule depends on the cancer type, the treatment given, and the condition of the rest of the liver.

Typical follow-up may include:

• Clinical review at regular intervals — often every 3 to 6 months for the first two to three years, then less frequently.
• Imaging of the liver (CT or MRI) on a similar schedule.
• Tumour markers (such as AFP for HCC) at each visit.
• Liver function tests and other blood tests.
• For transplant recipients: monitoring of immunosuppressive drug levels and surveillance for late complications.

The risk of recurrence is generally highest in the first two to three years after surgery and is greater in patients with underlying cirrhosis or with adverse features on pathology. If recurrence is found, further treatment — another resection, ablation, locoregional therapy, systemic therapy, or in some cases salvage transplant — may still be possible.

Complications

Treatment of liver cancer carries real risks. Knowing what they are helps with informed decision-making and with recognising early signs of problems.

From surgery

• Bleeding, sometimes requiring transfusion
• Infection of the wound or inside the abdomen
• Blood clots in the legs or lungs
• Pneumonia and other chest complications
• Bile leak from the cut surface of the liver
• Liver failure if the remaining liver is too small or already too damaged — one of the most serious complications of major resection
• Ascites (fluid in the abdomen) or pleural effusion (fluid around the lung)
• Injury to blood vessels or bile ducts

From transplantation

• Rejection of the new liver by the immune system, managed with immunosuppressive medicines
• Infection related to immunosuppression
• Hepatic artery thrombosis — a clot in the main artery to the new liver
• Bile duct strictures — narrowing where the bile duct was joined
• Long-term effects of immunosuppression, including kidney problems, diabetes, high blood pressure, and an increased risk of certain infections and skin cancers
• Recurrence of the original liver disease in the new liver, such as viral hepatitis — now much better controlled with modern antiviral therapy

From locoregional therapy

• Post-embolisation syndrome (fever, pain, nausea) after TACE
• Liver function worsening, particularly in patients with significant cirrhosis
• Bile duct injury, abscess, or bleeding (uncommon)
• Radiation-related effects with TARE or SBRT

From systemic therapy

• Fatigue, diarrhoea, skin and nail changes, high blood pressure, and other side effects of targeted therapy
• Immune-related side effects with immunotherapy, which can affect the skin, gut, liver, lungs, thyroid, and other organs, and need prompt recognition and treatment
• Bone marrow effects, mouth sores, nausea, and infection risk with chemotherapy

Risk is generally reduced when care is provided at experienced centres with multidisciplinary teams familiar with liver cancer.

Living with Liver Cancer

Living with a liver cancer diagnosis — whether in active treatment, in follow-up after curative treatment, or in long-term management — involves attention to both the cancer and to general liver health.

Treating the underlying liver disease

Because most HCC develops in a background of chronic liver disease, treating that disease is part of cancer care. This may include:

• Antiviral therapy for hepatitis B (long-term) or hepatitis C (a finite course with modern direct-acting antivirals)
• Avoiding alcohol
• Managing weight, blood sugar, and cholesterol if fatty liver disease is present
• Vaccination against hepatitis A and B if not already immune
• Careful use of medicines that affect the liver, including some painkillers and supplements

Nutrition

Malnutrition is common in advanced liver disease and liver cancer and can worsen recovery from treatment. A balanced diet with adequate protein is important. Some patients benefit from review by a dietitian familiar with liver disease, particularly before and after surgery.

Physical activity

Staying as active as your condition allows helps with energy, mood, and physical function. Gentle, regular walking is a good starting point. Specific advice will depend on where you are in treatment.

Emotional and practical wellbeing

A liver cancer diagnosis is heavy news. Many patients and family members experience anxiety, low mood, sleep difficulty, and uncertainty about the future. These reactions are normal. Support from family, peer support groups, counselling, or mental health professionals can help. Practical planning — arranging help at home, managing work, and organising paperwork — can reduce stress at difficult moments.

After successful treatment

Many patients who have completed treatment with curative intent return to meaningful, active lives. The shape of that life depends on which treatments you had, on the underlying liver condition, and on follow-up requirements. For transplant recipients, lifelong immunosuppressive medication, careful infection awareness, and regular monitoring become a routine part of life.

Outcomes and Outlook

Outcomes after treatment for liver cancer depend strongly on the type of cancer, the stage at diagnosis, the condition of the rest of the liver, and how completely the cancer can be treated. Early-stage HCC treated with resection or transplantation at experienced centres has substantially better long-term outcomes than advanced disease. Outcomes for intrahepatic cholangiocarcinoma are generally lower and depend heavily on stage and margins. Outcomes for colorectal liver metastases after complete resection can be encouraging in selected patients.

General survival statistics drawn from international literature can give a broad sense of the range but cannot predict an individual outcome. A realistic, personalised estimate is best obtained from your treating team, who can interpret your specific scans, pathology, liver function, and overall health.

Prevention of Progression and New Tumours

People who have had liver cancer remain at increased risk of new tumours in the liver, particularly if there is underlying chronic liver disease. Steps that may reduce risk include:

• Treating chronic hepatitis B with long-term antiviral therapy
• Treating chronic hepatitis C with curative direct-acting antivirals
• Avoiding alcohol
• Managing diabetes, weight, and cholesterol
• Stopping smoking
• Attending follow-up appointments and imaging
• Vaccination against hepatitis A and B if not already protected

For people with cirrhosis, ongoing surveillance with ultrasound and AFP every 6 months is recommended by major societies to detect any new tumours early, when treatment options are widest.

When to Seek Urgent Care

During and after treatment for liver cancer, certain symptoms need prompt medical attention. Contact your team or go to a hospital if you develop:

• New or worsening yellowing of the skin or eyes
• Severe abdominal pain
• Vomiting blood or passing black, tarry stools
• Sudden swelling of the abdomen or legs
• Confusion, marked drowsiness, or difficulty waking
• High fever, particularly if you are on immunosuppression or chemotherapy
• Heavy bleeding or unusual bruising
• Severe shortness of breath or chest pain

These can be signs of complications of the cancer, of treatment, or of advanced liver disease, and benefit from urgent assessment.

Liver Cancer in Children

Liver cancer is uncommon in children. The most frequent type in young children is hepatoblastoma, which usually occurs in children under five years of age. Older children and adolescents can develop hepatocellular carcinoma, sometimes in the setting of underlying liver disease such as biliary atresia or chronic hepatitis B.

Paediatric liver cancer is managed by paediatric oncology teams, often within international protocols developed by groups such as the Children’s Oncology Group and SIOPEL (the international childhood liver tumour group). Key features of treatment include:

• Chemotherapy is typically given before surgery to shrink the tumour and make complete removal possible.
• Surgical resection or, in selected cases, liver transplantation is the cornerstone of cure.
• Outcomes for hepatoblastoma, particularly in early stages, are substantially better than for adult liver cancer, with high cure rates reported in international series.
• Children require long-term follow-up to monitor for late effects of treatment, including effects on growth, hearing, heart, and kidney function.

Care for a child with liver cancer is best provided at a paediatric centre with experience in childhood liver tumours and access to paediatric HPB surgery and, when needed, paediatric transplantation.

Frequently Asked Questions

What is the difference between primary and secondary liver cancer?

Primary liver cancer begins in the liver itself — the most common type is hepatocellular carcinoma. Secondary liver cancer is cancer that started somewhere else in the body and has spread to the liver. The treatments differ, because secondary liver cancer is generally treated as the original cancer type that has spread, while primary liver cancer follows liver cancer protocols.

How is the choice between resection and transplant made?

The decision rests mainly on the condition of the rest of the liver. If the liver is otherwise healthy or has only mild disease, resection may be preferred. If there is significant cirrhosis or advanced underlying liver disease, transplantation may offer a better outcome because it treats both the cancer and the diseased liver. Other factors include tumour size and number, age, overall health, and donor availability. Your multidisciplinary team weighs these together.

Can the liver really grow back after part of it is removed?

Yes. The liver is unusual among organs in its ability to regenerate. After a major resection, the remaining liver typically regrows to near-normal volume within a few months, provided the remaining liver tissue is healthy.

What are the Milan criteria?

The Milan criteria are tumour size and number rules used to decide whether a patient with HCC is suitable for liver transplant. They are: a single tumour up to 5 cm, or up to three tumours each up to 3 cm, with no major blood vessel involvement and no spread outside the liver. Patients within these criteria have historically had the best long-term results after transplant. Some centres also use extended criteria for selected patients.

Will I need chemotherapy?

It depends on the type of cancer and its stage. For colorectal liver metastases, chemotherapy is commonly part of the overall plan. For intrahepatic cholangiocarcinoma, chemotherapy is often used both for advanced disease and after surgery. For HCC, traditional chemotherapy plays a smaller role; modern systemic treatment for advanced HCC is more often immunotherapy or targeted therapy. Your oncologist will discuss what current guidelines suggest for your situation.

What is immunotherapy and is it suitable for liver cancer?

Immunotherapy uses medicines that help the body’s own immune system recognise and attack cancer cells. For advanced HCC, combinations such as atezolizumab with bevacizumab are described as a standard first-line option in many international guidelines. Immunotherapy is also being studied in earlier stages and in combination with other treatments. Whether it is appropriate in an individual case depends on the cancer type, stage, liver function, and other medical factors.

Can liver cancer come back after treatment?

Yes, recurrence is possible, particularly in the first two to three years after surgery. It is more common when there is underlying cirrhosis or when pathology shows adverse features such as involvement of small blood vessels in the tumour. Regular follow-up aims to detect recurrence early, when more treatment options are available.

Is living liver donation safe for the donor?

Living liver donation is taken very seriously and donors are carefully selected through a complete medical and psychological assessment. The remaining liver in the donor regenerates over weeks, and most donors return to normal life and activity. The operation does carry risks, which the donor team discusses in detail. Donation is voluntary and uncoerced, and donors are free to decline at any point.

Does diet or alternative medicine cure liver cancer?

No diet or alternative medicine has been shown to cure liver cancer. Good nutrition supports the body during treatment, and some lifestyle steps — avoiding alcohol, treating viral hepatitis, managing weight — help liver health. Herbal products and supplements should always be reviewed with the medical team, because some can affect the liver or interact with treatments.

What lifestyle changes help long-term outcomes?

Avoiding alcohol, maintaining a healthy weight, treating hepatitis B or C if present, controlling diabetes, eating a balanced diet, and staying active all support liver health. Stopping smoking is encouraged for general and treatment-related reasons. Vaccinations and avoidance of medicines that stress the liver are also part of long-term care, particularly after transplant.

Conclusion

Liver cancer is a group of conditions rather than one disease, and treatment depends as much on the rest of the liver and on overall health as it does on the tumour itself. Modern care brings together surgery, transplantation, locoregional therapies, and a fast-evolving range of systemic treatments — with multidisciplinary teams choosing the combination that best fits an individual situation. For many patients, this combination offers a realistic chance of long-term control or cure; for others, the focus is on slowing the disease and maintaining quality of life for as long as possible.

A patient and family who understand the overall shape of the options — what each treatment offers, what it asks of the body, and what follow-up looks like — are well placed to have meaningful conversations with their treating team and to make the decisions that fit their situation best.